ALLOGENE THERAPEUTICS INC. - COMMON STOCK

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

13 Aug 2025 13:05:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

06 Aug 2025 05:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

01 Aug 2025 05:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

01 Jun 2025 07:45:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

23 May 2025 05:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

22 May 2025 14:17:55 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

13 May 2025 13:05:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

06 May 2025 05:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

23 Apr 2025 07:12:13 By Nasdaq GlobeNewswire

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

07 Apr 2025 05:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

13 Mar 2025 13:02:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

03 Mar 2025 05:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in March Investor Conference

26 Feb 2025 05:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

25 Feb 2025 13:10:07 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

13 Feb 2025 13:30:30 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in February Investor Conferences

04 Feb 2025 05:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer

29 Jan 2025 05:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

28 Jan 2025 05:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

16 Dec 2024 05:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

12 Dec 2024 05:30:00 By Nasdaq GlobeNewswire